ICON Launches New Patient Safety Service for Real-time Analysis of Aggregated Safety Data
09 Octobre 2013 - 1:01PM
Business Wire
Latest ICONIK service enables more informed,
data driven decisions regarding patient treatment and
safety
ICON plc, (NASDAQ: ICLR) a global provider of outsourced
development services to the pharmaceutical, biotechnology and
medical device industries, today launched ICONIK Patient Safety,
the latest service to leverage its ICONIK technology platform.
Identifying potentially significant clinical issues in
real-time, ICONIK Patient Safety offers a systematic way to monitor
safety trends in accumulating data, spot potential safety issues
and take appropriate corrective and preventative action while the
study is on-going. Data can be queried dynamically at any level of
detail (single patient, single site, across an entire study or
entire compound), helping sponsors make informed, data driven
decisions regarding patient treatment and safety, study direction
and regulatory reporting. ICONIK Patient Safety eliminates the
lengthy, manual review of individual patient files, allowing a
faster and easier review of aggregated safety events across study
populations.
Commenting on the new service, Dr. Peter Schueler, Senior Vice
President Medical & Safety Services, ICON Clinical Research,
said: “Patient wellbeing is paramount in any clinical trial. ICONIK
Patient Safety allows real-time review of integrated patient safety
data, thereby improving our ability to identify and monitor
unexpected adverse events. ICONIK Patient Safety helps study teams
maintain a view of a drug’s evolving safety profile by accumulating
safety data in real-time and allowing for quick identification of
emerging safety issues, affording greater protection of patients’
well-being. Before ICONIK Patient Safety, this level of dynamic
analysis and management of patient safety was simply not
possible.”
ICONIK Patient Safety is the latest service to leverage the
ICONIK technology platform and follows ICON’s recent announcement
of ICONIK Monitoring, a new service that improves quality and
reduces the costs of clinical development through more effective
use of monitoring resources.
The statements made in this press release may contain
forward-looking statements that involve a number of risks and
uncertainties. A description of risks and uncertainties relating to
ICON and its business can be found in Forms 20-F for the fiscal
year ended December 31st 2012 and in the other forms filed with the
US Securities and Exchange Commission, including the F-1, S-8 and
F-3. ICON disclaims any intent or obligation to update these
forward-looking statements.
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has approximately 10,170 employees, operating from 78 locations in
37 countries.
Further information is available at www.iconplc.com
ICON/ICLR-G
For ICONJulia BourneWeber ShandwickTel: +44 (0)20 7067
0492jbourne@webershandwick.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024